Mechanism of action

The historical papers investigated metabolic observations rather than establishing a single receptor mechanism. Ng and Bornstein (1978) included 176-191 among several C-terminal fragments examined in rats and described transient glucose and insulin changes with altered insulin sensitivity. Ma et al. (1982) studied both 176-191 and 177-191 in rat and isolated-tissue systems, assessing glycogen synthase, pyruvate dehydrogenase and metabolite changes. The tested sequence and model are integral to each finding. These measurements do not identify a validated human target or show that every short C-terminal fragment reproduces the action of the full GH protein.

State of evidence

The two direct fragment-series studies concern preclinical models and provide no controlled human weight-loss outcome for native 176-191. Wu and Ng's 1993 paper is a comparator on the adjacent 177-191 fragment, not another experiment on the identical sequence. It reported changes in lipid synthesis without a significant lipolytic effect in the stated glycerol-release assay. Reduced synthesis of lipid and increased breakdown of stored lipid are different processes. AOD-9604 introduces another identity boundary because its modified sequence and human-development program cannot be assigned to native 176-191 through a commercial fragment name. The selected evidence establishes a limited research context; it does not determine clinical benefit, human safety or systemic exposure for this exact fragment.

Questions about the research

Does a C-terminal fragment retain the full hormone's properties?

Not automatically. It contains only part of the sequence of the predominant 191-residue GH protein and has a different overall structure. Shared residues do not establish the complete protein's receptor interaction or clinical effects.

Can an AOD-9604 clinical trial be described as a 176-191 trial?

No. AOD-9604 is the modified Tyr-hGH(177-191) peptide. The native fragment's sequence must remain distinct from that modification, its formulation and its development history. Similar product terminology is not evidence of chemical identity.

Is an antilipogenic observation the same as a fat-burning effect?

No. Antilipogenic findings concern reduced lipid synthesis, while lipolysis concerns lipid breakdown. Even the adjacent-fragment comparator assessed those processes separately. A rat or isolated-tissue result cannot establish human weight reduction or the effects of a different sequence.

Sources

1. Ng and Bornstein, Am J Physiol 1978DOI: 10.1152/ajpendo.1978.234.5.E521PMID: 645904
2. Ma et al., Biochim Biophys Acta 1982DOI: 10.1016/0304-4165(82)90033-2PMID: 6810951
3. Wu and Ng, Biochem Mol Biol Int 1993, separate 177-191 comparatorPMID: 8358331

Mechanism of action

The historical papers investigated metabolic observations rather than establishing a single receptor mechanism. Ng and Bornstein (1978) included 176-191 among several C-terminal fragments examined in rats and described transient glucose and insulin changes with altered insulin sensitivity. Ma et al. (1982) studied both 176-191 and 177-191 in rat and isolated-tissue systems, assessing glycogen synthase, pyruvate dehydrogenase and metabolite changes. The tested sequence and model are integral to each finding. These measurements do not identify a validated human target or show that every short C-terminal fragment reproduces the action of the full GH protein.

State of evidence

The two direct fragment-series studies concern preclinical models and provide no controlled human weight-loss outcome for native 176-191. Wu and Ng's 1993 paper is a comparator on the adjacent 177-191 fragment, not another experiment on the identical sequence. It reported changes in lipid synthesis without a significant lipolytic effect in the stated glycerol-release assay. Reduced synthesis of lipid and increased breakdown of stored lipid are different processes. AOD-9604 introduces another identity boundary because its modified sequence and human-development program cannot be assigned to native 176-191 through a commercial fragment name. The selected evidence establishes a limited research context; it does not determine clinical benefit, human safety or systemic exposure for this exact fragment.

Questions about the research

Does a C-terminal fragment retain the full hormone's properties?

Not automatically. It contains only part of the sequence of the predominant 191-residue GH protein and has a different overall structure. Shared residues do not establish the complete protein's receptor interaction or clinical effects.

Can an AOD-9604 clinical trial be described as a 176-191 trial?

No. AOD-9604 is the modified Tyr-hGH(177-191) peptide. The native fragment's sequence must remain distinct from that modification, its formulation and its development history. Similar product terminology is not evidence of chemical identity.

Is an antilipogenic observation the same as a fat-burning effect?

No. Antilipogenic findings concern reduced lipid synthesis, while lipolysis concerns lipid breakdown. Even the adjacent-fragment comparator assessed those processes separately. A rat or isolated-tissue result cannot establish human weight reduction or the effects of a different sequence.

Sources

1. Ng and Bornstein, Am J Physiol 1978DOI: 10.1152/ajpendo.1978.234.5.E521PMID: 645904
2. Ma et al., Biochim Biophys Acta 1982DOI: 10.1016/0304-4165(82)90033-2PMID: 6810951
3. Wu and Ng, Biochem Mol Biol Int 1993, separate 177-191 comparatorPMID: 8358331